Cvrx, Inc. ( (CVRX) ) has released its Q3 earnings. Here is a breakdown of the information Cvrx, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CVRx, Inc. is a commercial-stage medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, with its flagship product, Barostim, being the first FDA-approved technology of its kind for heart failure patients.
In its third-quarter 2025 financial results, CVRx reported a 10% increase in total revenue compared to the previous year, reaching $14.7 million. The company also highlighted the growth of active implanting centers in the U.S. and the favorable CMS ruling on physician fee payment levels, which are expected to enhance patient access and adoption of their Barostim technology.
Key financial metrics showed U.S. revenue at $13.5 million, driven by expansion into new sales territories and increased awareness of Barostim. European revenue also saw a 12% increase, although total revenue units decreased. The gross profit rose by 15%, with a notable improvement in gross margin due to higher selling prices and manufacturing efficiencies. However, the company reported a net loss of $12.9 million, slightly improved from the previous year’s $13.1 million loss.
Looking ahead, CVRx has updated its full-year revenue guidance to between $55.6 million and $56.6 million, with expectations of continued gross margin improvements. The company remains focused on expanding its market presence and enhancing the adoption of its Barostim technology, positioning itself for future growth in the cardiovascular medical device sector.